FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2049916206> ?p ?o ?g. }

• W2049916206 endingPage "2677" @default.
• W2049916206 startingPage "2665" @default.
• W2049916206 abstract "Background: The thiazolidinediones (TZDs), including rosiglitazone maleate and pioglitazone hydrochloride, are commonly prescribed in patients with type 2 diabetes mellitus. Although recent meta-analyses suggest there is an increased risk of myocardial infarction (MI) among rosiglitazone users, these findings were not supported by data from other studies. Objective: The goal of this research was to compare the risk of MI, coronary revascularization (CR), and sudden death in patients who began rosiglitazone therapy versus those who began pioglitazone therapy. Methods: This was a retrospective cohort study using information from a large health care database (with data available on ~14 million individuals). All initiators of rosiglitazone or pioglitazone from July 1, 2000, through March 31, 2007, for whom the first dispensing followed ≥6 months of health plan membership and the member's 18th birthday were identified. The propensity score method was used to create matched cohorts of patients in 3 treatment groups: TZD monotherapy, dual therapy (a TZD plus another antidiabetic agent), and TZD therapy with concomitant insulin. Follow-up continued to a change in treatment regimen, defined as regimen switch (ie, the addition of any antidiabetic agent to an existing regimen) or regimen stop (ie, the discontinuation of any component of the therapeutic regimen). Three outcomes that represent coronary heart disease were assessed for this analysis: MI, CR, and sudden death. The proportional hazards model, stratified by therapeutic regimen, was used to estimate hazard ratios (HRs) and 95% CIs of coronary heart disease risk associated with use of rosiglitazone relative to pioglitazone. Results: Among 47,501 matched pairs of rosiglitazone and pioglitazone users, 72,104 (75.9%) were receiving TZD monotherapy, 17,822 (18.8%) were receiving dual therapy, and 5076 (5.3%) were receiving TZD therapy with insulin. Mean follow-up was 9.6 months with regimen switch as the censoring event and 8.4 months with regimen stop as the censoring event. For MI, the HR was 1.35 (95% CI, 1.12–1.62) through regimen switch and 1.41 (95% CI, 1.13–1.75) through regimen stop. For the composite outcome of MI, CR, and/or sudden death, the HR was 1.09 (95% CI, 0.97–1.22) through regimen switch and 1.12 (95% CI, 0.98–1.27) through regimen stop. Conclusions: In this retrospective cohort analysis, MI was more common in users of rosiglitazone than in users of pioglitazone. The incidence of a combined end point of MI, CR, and/or sudden death in patients receiving rosiglitazone was not significantly different from that in patients receiving pioglitazone." @default.
• W2049916206 created "2016-06-24" @default.
• W2049916206 creator A5006195570 @default.
• W2049916206 creator A5010499068 @default.
• W2049916206 creator A5045255444 @default.
• W2049916206 creator A5073130199 @default.
• W2049916206 creator A5080151435 @default.
• W2049916206 date "2009-11-01" @default.
• W2049916206 modified "2023-10-17" @default.
• W2049916206 title "The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: A retrospective cohort study using a US health insurance database" @default.
• W2049916206 cites W1972136146 @default.
• W2049916206 cites W1973245422 @default.
• W2049916206 cites W1987941106 @default.
• W2049916206 cites W1998835456 @default.
• W2049916206 cites W2007702299 @default.
• W2049916206 cites W2010040970 @default.
• W2049916206 cites W2010444920 @default.
• W2049916206 cites W2040274922 @default.
• W2049916206 cites W2072205603 @default.
• W2049916206 cites W2081276121 @default.
• W2049916206 cites W2091815896 @default.
• W2049916206 cites W2098550863 @default.
• W2049916206 cites W2115211952 @default.
• W2049916206 cites W2115607452 @default.
• W2049916206 cites W2125827301 @default.
• W2049916206 cites W2127125241 @default.
• W2049916206 cites W2141855743 @default.
• W2049916206 cites W2144536191 @default.
• W2049916206 cites W4237004496 @default.
• W2049916206 cites W4239785890 @default.
• W2049916206 doi "https://doi.org/10.1016/j.clinthera.2009.11.003" @default.
• W2049916206 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20110009" @default.
• W2049916206 hasPublicationYear "2009" @default.
• W2049916206 type Work @default.
• W2049916206 sameAs 2049916206 @default.
• W2049916206 citedByCount "38" @default.
• W2049916206 countsByYear W20499162062012 @default.
• W2049916206 countsByYear W20499162062013 @default.
• W2049916206 countsByYear W20499162062014 @default.
• W2049916206 countsByYear W20499162062015 @default.
• W2049916206 countsByYear W20499162062016 @default.
• W2049916206 countsByYear W20499162062017 @default.
• W2049916206 countsByYear W20499162062018 @default.
• W2049916206 countsByYear W20499162062020 @default.
• W2049916206 crossrefType "journal-article" @default.
• W2049916206 hasAuthorship W2049916206A5006195570 @default.
• W2049916206 hasAuthorship W2049916206A5010499068 @default.
• W2049916206 hasAuthorship W2049916206A5045255444 @default.
• W2049916206 hasAuthorship W2049916206A5073130199 @default.
• W2049916206 hasAuthorship W2049916206A5080151435 @default.
• W2049916206 hasConcept C126322002 @default.
• W2049916206 hasConcept C134018914 @default.
• W2049916206 hasConcept C167135981 @default.
• W2049916206 hasConcept C207103383 @default.
• W2049916206 hasConcept C2777180221 @default.
• W2049916206 hasConcept C2778213512 @default.
• W2049916206 hasConcept C2778384471 @default.
• W2049916206 hasConcept C2778715236 @default.
• W2049916206 hasConcept C2779306644 @default.
• W2049916206 hasConcept C2780152017 @default.
• W2049916206 hasConcept C2781413609 @default.
• W2049916206 hasConcept C41008148 @default.
• W2049916206 hasConcept C44249647 @default.
• W2049916206 hasConcept C500558357 @default.
• W2049916206 hasConcept C555293320 @default.
• W2049916206 hasConcept C71924100 @default.
• W2049916206 hasConcept C77088390 @default.
• W2049916206 hasConceptScore W2049916206C126322002 @default.
• W2049916206 hasConceptScore W2049916206C134018914 @default.
• W2049916206 hasConceptScore W2049916206C167135981 @default.
• W2049916206 hasConceptScore W2049916206C207103383 @default.
• W2049916206 hasConceptScore W2049916206C2777180221 @default.
• W2049916206 hasConceptScore W2049916206C2778213512 @default.
• W2049916206 hasConceptScore W2049916206C2778384471 @default.
• W2049916206 hasConceptScore W2049916206C2778715236 @default.
• W2049916206 hasConceptScore W2049916206C2779306644 @default.
• W2049916206 hasConceptScore W2049916206C2780152017 @default.
• W2049916206 hasConceptScore W2049916206C2781413609 @default.
• W2049916206 hasConceptScore W2049916206C41008148 @default.
• W2049916206 hasConceptScore W2049916206C44249647 @default.
• W2049916206 hasConceptScore W2049916206C500558357 @default.
• W2049916206 hasConceptScore W2049916206C555293320 @default.
• W2049916206 hasConceptScore W2049916206C71924100 @default.
• W2049916206 hasConceptScore W2049916206C77088390 @default.
• W2049916206 hasIssue "11" @default.
• W2049916206 hasLocation W20499162061 @default.
• W2049916206 hasLocation W20499162062 @default.
• W2049916206 hasOpenAccess W2049916206 @default.
• W2049916206 hasPrimaryLocation W20499162061 @default.
• W2049916206 hasRelatedWork W1964594176 @default.
• W2049916206 hasRelatedWork W2020625666 @default.
• W2049916206 hasRelatedWork W2028316975 @default.
• W2049916206 hasRelatedWork W2045720668 @default.
• W2049916206 hasRelatedWork W2107966736 @default.
• W2049916206 hasRelatedWork W2110102664 @default.
• W2049916206 hasRelatedWork W2172062051 @default.
• W2049916206 hasRelatedWork W2340355954 @default.
• W2049916206 hasRelatedWork W2354249222 @default.

• next